# The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism

> **NCT02262026** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 49 (actual)

## Conditions studied

- Alcoholism

## Interventions

- **DRUG:** 125 mg AZD0530
- **DRUG:** 50 mg AZD0530
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02262026
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-01
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-04-26
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262026, "The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02262026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*